Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial

Jarczyk J, Wirtz R, Roghmann F, Juette H, Kriegmair MC, Worst TS, Sikic D, Wach S, Taubert H, Wullich B, Weyerer V, Stöhr R, Zengerling F, Bolenz C, Breyer J, Burger M, Porubsky S, Hartmann A, Erben P, Eckstein M (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

Publisher: OXFORD UNIV PRESS

City/Town: OXFORD

Pages Range: 378-+

Conference Proceedings Title: ANNALS OF ONCOLOGY

Event location: Barcelona

DOI: 10.1093/annonc/mdz249.038

Authors with CRIS profile

Involved external institutions

Universität Ulm Germany (DE) Ruprecht-Karls-Universität Heidelberg Germany (DE) STRATIFYER Molecular Pathology GmbH Germany (DE) Ruhr-Universität Bochum (RUB) Germany (DE) Universität Regensburg Germany (DE)

How to cite

APA:

Jarczyk, J., Wirtz, R., Roghmann, F., Juette, H., Kriegmair, M.C., Worst, T.S.,... Eckstein, M. (2019). Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial. In ANNALS OF ONCOLOGY (pp. 378-+). Barcelona, ES: OXFORD: OXFORD UNIV PRESS.

MLA:

Jarczyk, J., et al. "Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial." Proceedings of the 44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona OXFORD: OXFORD UNIV PRESS, 2019. 378-+.

BibTeX: Download